Pancreatic Cancer Research

ResearcherSanford ResearchActive in the last 2 years

Sheema Khan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6216-1470; OpenAlex author ID A5030239872. Sources: OpenAlex.

Their work

Papers
23 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 23

  1. Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Last author DOI 10.3389/fphar.2025.1543112↗
  2. Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Last author DOI 10.3389/fphar.2025.1662270↗
  3. CEACAM7 expression contributes to early events of pancreatic cancer. Co-author DOI 10.1016/j.jare.2023.02.013↗
  4. Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.04.029↗
  5. An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.11.029↗
  6. Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Co-author DOI 10.1038/s42003-022-04102-4↗
  7. Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. Co-author DOI 10.3390/biomedicines9121814↗
  8. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. First author DOI 10.1038/s41416-019-0629-9↗
  9. APE1 Promotes Pancreatic Cancer Proliferation through GFRα1/Src/ERK Axis-Cascade Signaling in Response to GDNF. Co-author DOI 10.3390/ijms21103586↗
  10. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2019.04.005↗
  11. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Co-author DOI 10.1016/j.nano.2019.102027↗
  12. Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Co-author DOI 10.3390/cells9010103↗
  13. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.003↗
  14. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. First author DOI 10.1038/s41389-018-0031-0↗
  15. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. First author DOI 10.1007/s11605-016-3222-z↗
  16. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1038/onc.2016.218↗
  17. miR-145: Revival of a Dragon in Pancreatic Cancer. First author PMID 28616589↗
  18. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2015.02.082↗
  19. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-2397↗
  20. Revisiting stroma in pancreatic cancer. Co-author DOI 10.18632/oncoscience.198↗
  21. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Co-author DOI 10.18632/oncotarget.2281↗
  22. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Co-author DOI 10.1158/0008-5472.can-13-1288↗
  23. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Co-author DOI 10.1158/1535-7163.mct-12-1227↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Subhash C. Chauhan · 23 shared papers, 2013–2025 · strength 2.46
  2. Murali Mohan Yallapu · 20 shared papers, 2013–2025 · strength 2.23
  3. Meena Jaggi · 19 shared papers, 2013–2024 · strength 1.70
  4. Stephen W. Behrman · 11 shared papers, 2014–2025 · strength 1.12
  5. Swati Dhasmana · 5 shared papers, 2023–2025 · strength 1.06
  6. Anupam Dhasmana · 5 shared papers, 2023–2025 · strength 1.06
  7. Sonam Kumari · 8 shared papers, 2017–2022 · strength 0.78
  8. Mohammed Sikander · 7 shared papers, 2014–2022 · strength 0.60
  9. Shafiul Haque · 3 shared papers, 2023–2024 · strength 0.59
  10. Bilal Bin Hafeez · 5 shared papers, 2017–2022 · strength 0.48
  11. Shabia Shabir · 2 shared papers, 2025 · strength 0.47
  12. Russell Moreland · 2 shared papers, 2025 · strength 0.47
  13. Saini Setua · 5 shared papers, 2017–2019 · strength 0.39
  14. Neeraj Chauhan · 6 shared papers, 2013–2019 · strength 0.33
  15. Vivek Kumar Kashyap · 3 shared papers, 2018–2022 · strength 0.30
  16. Upender Manne · 1 shared paper, 2023 · strength 0.18
  17. Farrukh Afaq · 1 shared paper, 2023 · strength 0.18
  18. Andrew E. Massey · 2 shared papers, 2019 · strength 0.17
  19. Zachary E. Stiles · 2 shared papers, 2018–2019 · strength 0.15
  20. Fathi T. Halaweish · 2 shared papers, 2015–2019 · strength 0.13
  21. Mehdi Chaib · 1 shared paper, 2022 · strength 0.13
  22. Mihwa Kim · 1 shared paper, 2020 · strength 0.10
  23. Yoo Duk Choi · 1 shared paper, 2020 · strength 0.10
  24. Subash C. Gupta · 1 shared paper, 2018 · strength 0.09
  25. Advait B. Shetty · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.